Atriva Therapeutics announces changes in its Management Team

• Prof. Oliver Planz to step down as CSO at Atriva by mid-year 2022
• Prof. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board

Tübingen and Frankfurt, Germany, March 22, 2022 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today that Prof. Dr. Oliver Planz will not extend his contract as Chief Scientific Officer (CSO) beyond June 30, 2022. The Atriva co-founder and co-inventor of its technology will continue to serve the company in an advisory capacity as Chairman of the Scientific Advisory Board and will further expand the Scientific Advisory Board.

Prof. Dr. Oliver Planz has served as executive advisor and CSO with Atriva Therapeutics since 2015 when the company was founded. He will continue as Head of the Research Group “Translational Immunology of Infection”, Department of Immunology at the Interfaculty Institute for Cell Biology at the Eberhard-Karls-University of Tübingen.

“On behalf of the Advisory Board and the company, I would like to thank Oliver Planz for his great commitment and constant dedication to Atriva. We greatly respect and appreciate the scientific successes and milestones Atriva has achieved to date under Oliver’s scientific leadership and look forward to a continued fruitful collaboration,” said Dr. Ulrich Dauer, Chairman of the Atriva Therapeutics Advisory Board.

“I also sincerely thank Oliver Planz for his contribution to Atriva Therapeutics. He was fully instrumental in bringing the company to where we stand today. We have already taken steps to hire a new, full-time CSO for Atriva. With the transition into late-stage clinical development as well as an expansion of the indications under investigation, Atriva is currently making vital decisions to set the right course for the future and to exploit all opportunities”, commented Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics.

The preclinical work for Atriva in the Tübingen laboratories will continue under the leadership of Prof. Planz, at least through the end of 2022. Corresponding agreements have already been concluded with all parties involved.

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies. It was set up by a team of leading scientists in viral research as well as seasoned industry experts. The company aims to develop a therapy platform to treat severe respiratory and systemic diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response in RNA viruses. Zapnometinib is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company is actively enrolling patients in a Phase II study to evaluate efficacy in hospitalized patients with COVID-19.^[i] A Phase II study in influenza is currently under preparation, as are further studies in COVID-19. The Company owns 11 patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies. The patent life runs through 2041. Atriva Therapeutics is based in Tübingen and Frankfurt, Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de

For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.

---

References:

[i]      RESPIRE – A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19